Butterfly Network, Inc. (NYSE: BFLY)

$4.11 ▲ +0.18 (+4.72%)

As of May 14, 2026 03:59 PM

Sector: Healthcare Industry: Medical Devices CIK: 0001804176

Market Cap 1.01 Bn

P/E -13.08

P/S 9.78

Div. Yield 0.00

ROIC (Qtr) 0.00

Revenue Growth (1y) (Qtr) 24.99

Add ratio to table...

About

Butterfly Network, Inc. is a pioneer of the Ultrasound-on-Chip™ semiconductor platform and a leader in semiconductor-based point of care ultrasound technology. The company combines proprietary hardware, intuitive software, services and educational offerings to make ultrasound more accessible. Its flagship solution enables clinicians to apply ultrasound information directly into clinical workflow through affordable pocket sized devices that pair with cloud connected software accessed via a mobile application. This combination of portable hardware...

Butterfly Network, Inc. is a pioneer of the Ultrasound-on-Chip™ semiconductor platform and a leader in semiconductor-based point of care ultrasound technology. The company combines proprietary hardware, intuitive software, services and educational offerings to make ultrasound more accessible. Its flagship solution enables clinicians to apply ultrasound information directly into clinical workflow through affordable pocket sized devices that pair with cloud connected software accessed via a mobile application. This combination of portable hardware and AI driven cloud linked software supports use in large health systems as well as in remote or resource limited settings.

Butterfly Network, Inc. generates revenue primarily from the sale of its handheld ultrasound devices, including the Butterfly iQ3, Butterfly iQ+, Butterfly iQ+ Bladder and Butterfly Move systems, along with related accessories such as cases, adaptors and carts. The company also offers software subscriptions—core, advanced and specialty plans—that provide cloud storage, image analysis, AI tools and workflow integration, and it sells professional services for large scale deployments, training and education. In addition, through its Butterfly Embedded™ program, it licenses its ultrasound‑on‑chip technology to third parties for co‑development of non competing applications, receiving up front fees, annual license payments and potential milestone based revenue. For the fiscal years ended December 31, 2025 and 2024, total revenue was $97.6 million and $82.1 million, respectively.

Butterfly Network, Inc. occupies a distinctive niche within the ultrasound industry by replacing traditional piezoelectric crystal probes with its semiconductor based Ultrasound‑on‑Chip™ platform, which eliminates lead based materials and enables compliance with EU RoHS standards without reliance on exemptions. While it competes with established manufacturers of cart based and handheld ultrasound systems, its technology offers whole body imaging on a single probe, lower power consumption and the ability to benefit from Moore's Law driven performance gains. The company further differentiates itself through AI enhanced software, cloud connectivity and a comprehensive ecosystem that includes tele guidance, automated measurement tools and education platforms, positioning it as a leader in the shift toward portable, affordable and digitally integrated point of care imaging.

Butterfly Network, Inc. serves a broad range of customers that includes hospitals, health systems, clinics, individual physicians, nurses and other healthcare professionals across various specialties. The company also sells to veterinarians and veterinary practices through its Butterfly iQ Vet line and works with non governmental organizations and global health partners to deploy its devices in low resource settings. Although specific customer names are not disclosed, the filing notes that Butterfly devices have been purchased by clinicians in most of the 100 largest U. S. healthcare systems.

Investment thesis

Bull case

Butterfly’s recent quarter demonstrated a clear shift from a “sell‑probes‑only” model to a platform‑centric strategy that positions the company for significant scale. The launch of iQ3 in 2024 and its rapid adoption, now accounting for 85 % of probe volume, underscores the market’s appetite for a semiconductor‑based, cloud‑connected device. Coupled with the announced entry of P5.1 into full‑scale production and the planned Apollo AI chip, the firm is poised to deliver higher‑quality imaging at lower cost, thereby reinforcing its competitive advantage over legacy piezo‑based handhelds. This technological leap, combined with an increasing focus on AI‑enabled clinical workflows, should accelerate enterprise sales and deepen penetration into hospital systems worldwide.
Clinical validation studies have become a powerful catalyst for adoption, yet management has not heavily highlighted them in public messaging. The Rutgers study, which documented a 35 % improvement in clinical management and a 30 % reduction in length of stay, offers hard economic data that can be leveraged to justify the higher cost of enterprise licenses. Similarly, the gestational‑age AI tool deployed in Malawi and Uganda demonstrates the platform’s applicability in low‑resource settings, potentially opening access to emerging markets that large competitors have not yet penetrated. These proof points not only support a higher valuation of the software component but also signal a broader shift toward value‑based reimbursement models that favor point‑of‑care solutions.
Security and regulatory compliance have been a differentiator that has been underemphasized by the market. Butterfly’s recent ISO 27001 certification, along with other international security accreditations, signals a robust cloud posture that is attractive to large health systems wary of data breaches. The company’s early adoption of FedRAMP and other U.S. government standards positions it favorably for federal contracts, which could drive a significant portion of future revenue. The strategic emphasis on secure, cloud‑enabled workflows may also reduce the time to market for future AI applications, creating a virtuous cycle of adoption and revenue growth.
The pipeline, while subject to seasonal timing, shows increasing activity as evidenced by the 30 % increase in U.S. and international revenue in Q3. Management’s assertion that the “cloud is lifting” reflects a broader acceptance of the platform’s enterprise software, which has already generated steady software and services revenue. With Compass AI on the cusp of launch, the company is likely to capture recurring subscription revenue, thereby improving the quality of earnings and providing a more predictable cash flow profile. This shift toward software‑driven margins should translate into higher profitability once the current operating leverage constraints are mitigated.
Butterfly’s balance sheet has improved markedly, with cash and equivalents rising to $148 million from $88 million a year earlier, giving the company a substantial runway to invest in R&D and go‑to‑market initiatives. The company’s non‑cash inventory write‑down, while painful on GAAP earnings, is a one‑off event that has sharpened the cost structure and brought adjusted gross margin to 64 %. This indicates that the firm’s underlying economics are becoming healthier and that the company can sustain its growth trajectory without additional capital injections for the near term. The strong cash position also offers a buffer against potential macroeconomic headwinds that could impact payment timing for large hospital contracts.

Butterfly’s recent quarter demonstrated a clear shift from a “sell‑probes‑only” model to a platform‑centric strategy that positions the company for significant scale. The launch of iQ3 in 2024 and its rapid adoption, now accounting for 85 % of probe volume, underscores the market’s appetite for a semiconductor‑based, cloud‑connected device. Coupled with the announced entry of P5.1 into full‑scale production and the planned Apollo AI chip, the firm is poised to deliver higher‑quality imaging at lower cost, thereby reinforcing its competitive advantage over legacy piezo‑based handhelds. This technological leap, combined with an increasing focus on AI‑enabled clinical workflows, should accelerate enterprise sales and deepen penetration into hospital systems worldwide.
Clinical validation studies have become a powerful catalyst for adoption, yet management has not heavily highlighted them in public messaging. The Rutgers study, which documented a 35 % improvement in clinical management and a 30 % reduction in length of stay, offers hard economic data that can be leveraged to justify the higher cost of enterprise licenses. Similarly, the gestational‑age AI tool deployed in Malawi and Uganda demonstrates the platform’s applicability in low‑resource settings, potentially opening access to emerging markets that large competitors have not yet penetrated. These proof points not only support a higher valuation of the software component but also signal a broader shift toward value‑based reimbursement models that favor point‑of‑care solutions.
Security and regulatory compliance have been a differentiator that has been underemphasized by the market. Butterfly’s recent ISO 27001 certification, along with other international security accreditations, signals a robust cloud posture that is attractive to large health systems wary of data breaches. The company’s early adoption of FedRAMP and other U.S. government standards positions it favorably for federal contracts, which could drive a significant portion of future revenue. The strategic emphasis on secure, cloud‑enabled workflows may also reduce the time to market for future AI applications, creating a virtuous cycle of adoption and revenue growth.
The pipeline, while subject to seasonal timing, shows increasing activity as evidenced by the 30 % increase in U.S. and international revenue in Q3. Management’s assertion that the “cloud is lifting” reflects a broader acceptance of the platform’s enterprise software, which has already generated steady software and services revenue. With Compass AI on the cusp of launch, the company is likely to capture recurring subscription revenue, thereby improving the quality of earnings and providing a more predictable cash flow profile. This shift toward software‑driven margins should translate into higher profitability once the current operating leverage constraints are mitigated.
Butterfly’s balance sheet has improved markedly, with cash and equivalents rising to $148 million from $88 million a year earlier, giving the company a substantial runway to invest in R&D and go‑to‑market initiatives. The company’s non‑cash inventory write‑down, while painful on GAAP earnings, is a one‑off event that has sharpened the cost structure and brought adjusted gross margin to 64 %. This indicates that the firm’s underlying economics are becoming healthier and that the company can sustain its growth trajectory without additional capital injections for the near term. The strong cash position also offers a buffer against potential macroeconomic headwinds that could impact payment timing for large hospital contracts.

Bear case

The GAAP gross margin of negative 17.5 % in Q3 is a stark reminder that the company is still grappling with significant cost distortions. The $17.4 million inventory write‑down, a consequence of an overestimation of iQ+ demand, demonstrates the volatility of the company’s supply chain assumptions. Such material write‑downs can erode investor confidence and may prompt further adjustments if the company misjudges future chip demand or faces similar inventory misalignments. Until the company can reliably forecast demand and optimize its inventory cycles, the GAAP margin risk remains a pressing concern.
Butterfly’s cash burn, though reduced, remains substantial relative to its revenue base. The adjusted EBITDA loss of $8.1 million in Q3, alongside a net loss of $33.0 million, indicates that the firm is not yet generating positive operating cash flow. Even with a strong cash balance, continued cash outflows for R&D, sales, and marketing could deplete reserves if enterprise deals do not materialize as expected. This creates a scenario where the company may need to raise additional capital, potentially diluting shareholders or diverting focus from product development.
Enterprise adoption has been slower than anticipated, as evidenced by the company’s candid admission of purchase delays driven by macro‑economic conditions. The Q&A highlighted that hospitals are postponing capital expenditures due to broader economic pressures, which directly impacts the company’s ability to close large deals. Moreover, the reliance on “enterprise sales” to drive growth exposes the business to cyclical capital budgets that are subject to payer negotiations and reimbursement policy changes. These factors could dampen revenue growth and increase the time horizon to reach breakeven.
Management’s focus on education as a barrier to adoption, while valid, is not a scalable solution for the enterprise market. The company’s current strategy of in‑person training and advanced AI tools may not sufficiently address the skill gaps in large health systems, where standardized protocols and regulatory oversight require more robust validation. Additionally, the churn in individual subscription revenue, driven by lower renewal rates, suggests that the customer lifetime value may be lower than projected, especially if enterprise customers do not adopt the subscription model as aggressively. This risk could undermine the anticipated shift toward recurring revenue streams.
Competitive pressure from larger incumbents cannot be ignored. The market still hosts a number of well‑capitalized companies that have recently invested in semiconductor‑based handhelds and cloud platforms, such as those highlighted in industry awards. These players possess deeper pockets for R&D and marketing, allowing them to potentially out‑compete Butterfly in price, feature set, and distribution channels. If competitors successfully bring their own AI‑enabled, secure cloud solutions to market, Butterfly’s unique value proposition may erode, forcing the company into a price‑war scenario.

The GAAP gross margin of negative 17.5 % in Q3 is a stark reminder that the company is still grappling with significant cost distortions. The $17.4 million inventory write‑down, a consequence of an overestimation of iQ+ demand, demonstrates the volatility of the company’s supply chain assumptions. Such material write‑downs can erode investor confidence and may prompt further adjustments if the company misjudges future chip demand or faces similar inventory misalignments. Until the company can reliably forecast demand and optimize its inventory cycles, the GAAP margin risk remains a pressing concern.
Butterfly’s cash burn, though reduced, remains substantial relative to its revenue base. The adjusted EBITDA loss of $8.1 million in Q3, alongside a net loss of $33.0 million, indicates that the firm is not yet generating positive operating cash flow. Even with a strong cash balance, continued cash outflows for R&D, sales, and marketing could deplete reserves if enterprise deals do not materialize as expected. This creates a scenario where the company may need to raise additional capital, potentially diluting shareholders or diverting focus from product development.
Enterprise adoption has been slower than anticipated, as evidenced by the company’s candid admission of purchase delays driven by macro‑economic conditions. The Q&A highlighted that hospitals are postponing capital expenditures due to broader economic pressures, which directly impacts the company’s ability to close large deals. Moreover, the reliance on “enterprise sales” to drive growth exposes the business to cyclical capital budgets that are subject to payer negotiations and reimbursement policy changes. These factors could dampen revenue growth and increase the time horizon to reach breakeven.
Management’s focus on education as a barrier to adoption, while valid, is not a scalable solution for the enterprise market. The company’s current strategy of in‑person training and advanced AI tools may not sufficiently address the skill gaps in large health systems, where standardized protocols and regulatory oversight require more robust validation. Additionally, the churn in individual subscription revenue, driven by lower renewal rates, suggests that the customer lifetime value may be lower than projected, especially if enterprise customers do not adopt the subscription model as aggressively. This risk could undermine the anticipated shift toward recurring revenue streams.
Competitive pressure from larger incumbents cannot be ignored. The market still hosts a number of well‑capitalized companies that have recently invested in semiconductor‑based handhelds and cloud platforms, such as those highlighted in industry awards. These players possess deeper pockets for R&D and marketing, allowing them to potentially out‑compete Butterfly in price, feature set, and distribution channels. If competitors successfully bring their own AI‑enabled, secure cloud solutions to market, Butterfly’s unique value proposition may erode, forcing the company into a price‑war scenario.

Timing of Transfer of Good or Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	145.93 Bn	23.33	3.23	34.05 Bn
2	SYK	Stryker Corp	115.71 Bn	34.62	4.58	14.72 Bn
3	MDT	Medtronic plc	97.69 Bn	21.17	2.75	28.07 Bn
4	BSX	Boston Scientific Corp	78.71 Bn	22.00	3.82	11.03 Bn
5	EW	Edwards Lifesciences Corp	47.63 Bn	44.75	7.85	0.60 Bn
6	PHG	Koninklijke Philips Nv	29.38 Bn	13,009.40	1.46	8.07 Bn
7	DXCM	Dexcom Inc	22.72 Bn	24.58	4.72	-
8	STE	STERIS plc	20.71 Bn	29.06	3.55	1.90 Bn

Research Tools